Wells Fargo maintains Fate Therapeutics at Equal-Weight, lowers price target to $3 from $3.50
Wells Fargo kept Fate Therapeutics at Equal-Weight but cut its price target to $3 from $3.50, a 14.3% reduction. This implies a 62.2% upside from the Nov 5 close of $1.85, according to the bank.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short‑term selling pressure but does not change the underlying Equal‑Weight stance.
Market read
Analyst target reduction is a modest catalyst for a small‑cap biotech, offering a short‑term trading edge.
What to watch
Recent clinical trial updates not mentioned may offset the downgrade.
Background
Wells Fargo maintains an Equal‑Weight rating on Fate Therapeutics while adjusting its price target.
Ticker impact
Wells Fargo lowered its price target on Fate Therapeutics to $3 from $3.50, indicating a 14.3% reduction.
likely downside as the market prices in the lower target
Analyst downgrade typically leads to short-term price weakness, especially for a small‑cap biotech.
Market effects
May weigh on other small‑cap biotech stocks as analysts tighten targets.
Limited to U.S. biotech sector.
Low
Counterpoint
Target cut could be an overreaction; upside potential remains if upcoming trial data exceeds expectations.
Key entities
- AnalystWells Fargo
Provides research coverage and price target for Fate Therapeutics.
- CompanyFate Therapeutics
Biotech firm listed on Nasdaq (FATE).